MedTrace Logo

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

NCT01603277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-02-02

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.

Conditions

  • Moderate-to-Severe Asthma

Interventions

BIOLOGICAL

Anti-GM-CSF Monoclonal Antibody 400mg

Anti-GM-CSF Monoclonal Antibody 400mg

OTHER

Placebo

Normal Saline

Sponsors & Collaborators

  • Humanigen, Inc.

    lead INDUSTRY

Principal Investigators

  • Nestor A. Molfino, MD, MSc · KaloBios Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2014-01-31

Countries

  • United States
  • Australia
  • France
  • Poland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01603277 on ClinicalTrials.gov